Lessons from landmark trials with PCSK9i: Why, who and how to manage patients at increased CV risk?
EBAC-accredited E-LearningOnline-CME - This course consists of 4 separate lectures
This CME accredited course consists of 4 separate short (12 - 15 minute) lectures. View and complete all 4 items separately and earn 1 CME credit
In this educational programme the role of PCSK9 inhibitors in the management of patients at increased CV risk will be discussed, based on new data from recent landmark outcome trials.
This course consists of the following 4 lectures
- PCSK9 inhibitors: How do they work? - Prof. John Chapman, PhD Pitié-Salpêtrière University Hospital, Paris, France
- Landmark trials with PCSK9 inhibitors- Prof. Gabriel Steg, MD - Hôpital Bichat, Paris, France
- Guidelines and the role of non-statin therapies for high risk ASCVD patients- Prof. Wouter Jukema,MD - Leiden University Medical Center, The Netherlands
- Identifying patients for PCSK9 therapy - Prof. Kees Hovingh, MD - Amsterdam University Medical Centers, The Netherlands
Educational objectives of this course are to:
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients at increased CV risk and with FH
- Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
- Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
- To explore treatment options in a statin-intolerant high risk patient in order to reach LDL-C goal
- Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
- Understand the implications of new ESC guidelines for lipid management
- Prof. John Chapman PhD - Research Professor at the Pierre and Marie Curie University, and Director Emeritus of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpêtrière University Hospital in Paris, France
- Prof. Ph. Gabriel Steg, MD - cardiologist in the Hôpital Bichat, Paris, France and Professor at the National Heart and Lung Institute, Imperial College, London, UK
- Prof. J. Wouter Jukema, MD - PhD, FESC, FACC, is Professor of Cardiology, an established Clinical Investigator of the Netherlands Heart Foundation, as well as Chairman of “Leiden Vascular Medicine” at Leiden University Medical Center (LUMC) in the Netherlands
- Prof. Kees Hovingh, MD - Internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam
This educational activity is designed for cardiologists and other healthcare professionals with an interest in treating patients with increased CV risk, ACS and lipid disorderes
This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
Supported by an unrestricted educational grant received from Sanofi-Regeneron
This is available as accredited online CME for members. Click the button below to enroll:Enroll